Skip to Content


Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Concerning Method for Production of Plasmodium Causing Relapsing Malaria

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble Start Printed Page 3169


U.S. Army Medical Research and Materiel Command, DOD.




In accordance with 37 CFR 404.6, announcement is made of the availability for licensing of U.S. Patent No. 6,090,614 entitled “Method for Production of Plasmodium Causing Relapsing Malaria,” issued 07/18/00. Foreign rights are also available (PCT/US97/13770). This patent has been assigned to the United States Government as represented by the Secretary of the Army.


Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, Maryland 21702-5012.

Start Further Info


For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619-6664. Both at telefax (301) 619-5034.

End Further Info End Preamble Start Supplemental Information


This invention provides for recycling parasites and maintaining long-term cultures of P.vivax and P.ovale. Preferred conditions include: (1) The immediate transfer of parasites to human reticulocytes during the first and second in vitro culture cycles, (2) the use of McCoy's 5A medium modified with L-glutamine containing 25 mM HEPES buffer supplemented with 20% human AB serum, (3) the continual addition of reticulocytes to the culture every 34-44 hours after the beginning of a new culture cycle and (4) the use of alternate static (growth and differentiation phase) and shaker (invasin phase) culture.

Start Signature

Luz D. Ortiz,

Army Federal Register Liaison Officer.

End Signature End Supplemental Information

[FR Doc. 02-1644 Filed 1-22-02; 8:45 am]